Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder
Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Summary
This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of KH607 in 120 participants diagnosed with moderate or severe Major Depressive Disorder.
Official title: A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KH607 in the Treatment of Adult Participants With Moderate or Severe Major Depressive Disorder
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2025-08
Completion Date
2026-04
Last Updated
2025-08-03
Healthy Volunteers
No
Conditions
Interventions
KH607 tablets
oral 30mg , once daily for 14 days
placebo
oral, once daily for 21 days
KH607 tablets
oral 20mg, once daily for 21 days
KH607 tablets
oral 30mg, once daily for 21 days